Skip to content

Menu
  • USC Stem Cell
  • About
    • Stem Cell FAQs
    • Mission and History
    • California’s Leadership in Stem Cell Research
    • Founding Supporters and Ambassadors
    • Well-being
    • Jobs
  • News & Events
    • News
    • Events
    • Videos
    • Impact Reports and Newsletters
  • Research
    • Department Faculty
    • Eli and Edythe Broad Center Faculty
    • Research Facilities
    • Clinical Translation
    • USC+CHLA Alpha Clinic
    • Translational Research Committee
    • USC Stem Cell Research Oversight Committee (SCRO)
    • Apply to Become Center Faculty
  • Education & Training
    • Undergraduate
    • Master’s Program
    • PhD Program
    • Medical Education
    • Postdoctoral Opportunities
    • Our Trainees
  • Funding
  • Inclusive Excellence
  • Support Us
  • Contact
    • Directory
    • Subscribe
  • Search

For dogs with arthritis, pet pain relief effort could be a game-changer

By  Leigh Hopper

Posted July 20, 2023
Reading Time 3 minutes

in this section

  • News
  • Events
  • Videos
  • Impact Reports and Newsletters

read this next

From left, Denis Evseenko and Jay Lieberman (Photo by Sergio Bianco)

Potential relief for osteoarthritis moves to clinical trial after animal studies

  • Follow us on
  • Like us on
  • Follow us on
  • Follow us on
(Image courtesy of iStock)
(Image courtesy of iStock)

A USC researcher is launching a biopharmaceutical startup with backing from the university to develop a drug to slow premature aging and arthritis — in dogs.

Denis Evseenko, a professor of orthopedic surgery, stem cell research and regenerative medicine at the Keck School of Medicine of USC, is leading the effort to develop non-opioid pain relief and joint preservation for four-legged family members.

“Breeds like Labradors and Golden Retrievers become like family members. They live for 10 or 12 years, but by age 7 or 8 they have arthritis pain, and they have trouble moving,” Evseenko said. “Twenty years ago, it was very uncommon for dog owners to treat chronic diseases in their pets, but the culture has changed. Now people are treating cancer in dogs, doing surgeries. There’s a huge unmet need for arthritis treatment in animals as well.”

Dog arthritis: Common among canines

Arthritis is extremely common in dogs, affecting as many as 25%, according to the U.S. Food and Drug Administration.

The startup, called ReParris, aims to develop a therapeutic approach for animals and humans based on research findings Evseenko and his team reported in Science Translational Medicine earlier this year.

The ReParris drug is a chemical compound that targets a molecular pathway that normally signals when antibodies or immune cells should attack sick cells infected by a virus or infection. Studies in animal models suggest that the drug may block one of the receptor’s signaling cascades, disrupting the long-lasting inflammatory response excessively activated in immune phagocytes in subjects with osteoarthritis.

Benefits of dog arthritis drug

Evseenko’s research found that the chemical compound prevented systemic low-grade inflammation, reduced pain and increased activity in a mouse model of osteoarthritis; in addition, the drug appeared to promote tissue regeneration rather than scarring and slowed down premature aging in animals.

Delivered as a pill, the drug has the potential to extend life by reducing chronic systemic inflammation related to aging and also by reducing chronic musculoskeletal pain.

“Pain is often the reason why people will have their pets euthanized,” Evseenko said. “If we are able to extend their healthy life, that’s huge. That’s the holy grail. Our ultimate goal is to use this experience in veterinary medicine to develop a therapy that eventually can slow down premature aging in human patients.”

Co-founders of ReParris include R. Rex Parris, an attorney and mayor of Lancaster, Calif., who supports longevity research at USC; and Anja Skodda, CEO of HappyBond, a pet health care company.

Read more about: Musculoskeletal
Mentioned in this article: Denis Evseenko, MD, PhD

Post navigation

← Ten USC Stem Cell PhD students and recent graduates earn NIH fellowships
Stem Cell PhD student Alma Zuniga Munoz wins USC’s first Gilliam Fellowship from the Howard Hughes Medical Institute →
Keck School of Medicine of USC
1975 Zonal Ave.
Los Angeles, CA 90033
Google Map
Phone: (323) 442-1900
Hours:
Monday–Friday
7:30am–5:00pm PST
Resources For
  • Current Students
  • Faculty & Staff
  • Patients
  • Community
  • Press
  • Visitors
Areas of Focus
  • Education & Training
  • Research
  • Patient Care
  • Community
Departments and Offices
  • Departments
  • Institutes and Centers
  • Research Programs
  • Administrative Offices
About Keck
  • History
  • Leadership
  • Annual Report
  • Digital Accessibility
Intranet
  • Privacy Notice
  • Notice of Non-Discrimination
  • Smoke-Free Policy

Copyright © 2025 University of Southern California

  • Research
    • Research HomeCutting-edge research drives innovation in healthcare at the Keck School of Medicine
    • Where Research Happens
    • Research Funding
    • Training and Education
    • Researcher Resources
    • Collaborate and Partner
  • Education
    • Education HomeNurturing future healthcare leaders through excellence in education
    • MD Program
    • Residencies and Clinical Fellowships
    • PhD Programs
    • Master’s Programs
    • Professional Programs
    • Post-Doctoral Researchers
    • CME, Certificate & Undergraduate Programs
  • Departments, Institutes & Centers
    • Basic Science and Clinical DepartmentsExploring foundational science and specialized clinical fields
    • Institutes and Centers
    • Research Programs
  • About
    • About the Keck SchoolDiscover the mission, history, and vision of the Keck School of Medicine
    • History
    • Leadership
    • Dean’s Corner
    • Life in Southern California
    • Visit
  • Our Faculty
  • Current Students
  • Newsroom
  • Events Calendar
  • Support the Keck School
  • USC.edu
  • Are you a Patient?